Thera-SAbDab

OZORALIZUMAB

>   Structural Summary
TherapeuticOzoralizumab
Target 1TNFA
Heavy Chain 1EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRGQGTLVTVSS
Light Chain 1na
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 Structure5m2j [Fvs: D]
Target 2ALB
Heavy Chain 2EVQLVESGGGLVQPGNSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSSISGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLRPEDTAVYYCTIGGSLSRSSQGTLVTVSS
Light Chain 2na
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Ozoralizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 93.00%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 101 102 103 104 105 106 107 108 109 110 111 112 113
ozoralizumab_Fv1 E V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S D Y W M Y W V R Q A P G K G L E W V S E I N T N G L I T K Y P D S V K G R F T I S R D N A K N T L Y L Q M N S L R P E D T A V Y Y C A R S P S G - F N R G Q G T L V T V S S
5m2j Q V Q L V E S G G G L V Q P G G S L R L S C A A S G F T F S N Y W M Y W V R Q A P G K G L E W V S E I N T N G L I T K Y P D S V K G R F T I S R D N A K N T L Y L Q M N S L K P E D T A L Y Y C A R S P S G F N - R G Q G T Q V T V S S
>   Metadata
FormatBispecific Single Domains (VH-VH'-VH)
Isotypena
Highest Clinical Trial (Jan '20)Phase-III
Estimated Status (Jan '20)Active
Recorded Developmental TechnologyNanobody Technology
INN Year Proposed2011
INN Year Recommended2012
Companies InvolvedAblynx, Eddingpharm, Pfizer, Taisho Pharmaceutical
Conditions Approvedna
Conditions ActiveRheumatoid arthritis
Conditions DiscontinuedAnkylosing spondylitis, Crohn's disease, Psoriatic arthritis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]